Ib Acquisition CORP

IB Acquisition Corp. has extended its deadline to complete an initial business combination by six months to September 28, 2026, following stockholder approval.

IB Acquisition Corp. stockholders approved an extension for its business combination deadline until September 28, 2026, amidst significant share redemptions.

IB Acquisition Corp. and GNQ Insilico Inc. announced a joint initiative with a Fortune 100 global technology company to advance AI-driven drug discovery and precision medicine.

GNQ Insilico, an AI-powered drug development company, announced its plan to go public through a business combination with SPAC IB Acquisition Corp., valuing GNQ at $500 million.

IB Acquisition Corp. stockholders approved an extension for its business combination deadline to March 28, 2026, following significant share redemptions.

IB Acquisition Corp. has dismissed UHY LLP as its independent auditor and appointed MaloneBailey LLP, effective April 22, 2024 and April 24, 2024 respectively.

IB Acquisition Corp. has entered into a definitive business combination agreement with Canadian-based GNQ Insilico Inc. to take the company public.

IB Acquisition Corp. reported a net loss of $58,902 for the quarter ended December 31, 2025, and faces substantial doubt about its ability to continue as a going concern, despite extending its business combination deadline to March 28, 2026.

IB Acquisition Corp. reported Q3 2025 results, showing increased net income for the nine-month period but also disclosed substantial doubt about its ability to continue as a going concern due to liquidity challenges and the uncompleted business combination.

IB Acquisition Corp. reports a net income of $1.73 million for the six months ended March 31, 2025, driven by interest and dividends earned on cash and investments held in a trust account.

IB Acquisition Corp. reports a net income of $907,068 for the quarter ended December 31, 2024, driven by interest earned on marketable securities.

IB Acquisition Corp. reported a net income of $1.1 million for the quarter ended June 30, 2024, primarily driven by interest earned on marketable securities after completing its initial public offering.

IB Acquisition Corp. secured a business combination deadline extension to March 2026, but faced substantial share redemptions, significantly reducing its trust account balance.

IB Acquisition Corp.'s 10-K filing details its capital structure, including common stock, rights, and preferred stock, along with key governance provisions.

GNQ Insilico has entered a global marketing agreement with IBM to deploy its causal AI drug simulation and digital twin platforms.

AQR Capital Management entities reported the sale of common stock in IB Acquisition Corp., reducing their beneficial ownership.

AQR Capital Management Holdings and affiliates reported the sale of 4,619 shares of IB Acquisition Corp. common stock at $10.75 per share.

GNQ Insilico Inc. has entered a two-year joint initiative and marketing agreement with a Fortune 100 global technology company to advance AI-driven drug discovery and precision medicine solutions.

GNQ Insilico Inc., an AI-powered drug development company, will go public through a business combination with IB Acquisition Corp. (NASDAQ: IBAC), valuing GNQ at US$500 million.

AQR Capital Management Holdings and its affiliates sold 195,806 shares of IB Acquisition Corp. common stock for $10.44 per share.

IB Acquisition Corp. will hold a special meeting to vote on extending its business combination deadline to September 28, 2026, citing insufficient time to complete a deal.

IB Acquisition Corp. is seeking stockholder approval to extend its deadline for completing a business combination by six months, from September 28, 2025, to March 28, 2026.

IB Acquisition Corp. is seeking stockholder approval to extend its deadline to complete a business combination by six months, from September 28, 2025, to March 28, 2026.

IB Acquisition Corp., a blank check company, has filed an amendment to its S-1 registration statement for a $100 million initial public offering, aiming to pursue acquisitions in fintech, healthcare, consumer goods and other sectors.

IB Acquisition Corp., a blank check company, files an amendment to its S-1 registration statement for a proposed $100 million initial public offering.

AQR Capital Management, LLC, AQR Capital Management Holdings, LLC, and AQR Arbitrage, LLC have filed a Schedule 13G indicating zero beneficial ownership of IB Acquisition Corp. common stock as of March 31, 2026.

AQR Capital Management and its affiliates reported a 12% beneficial ownership stake in IB Acquisition Corp., holding 688,646 shares of common stock.

Bank of Montreal and its affiliates have filed an amended Schedule 13G, reporting no beneficial ownership in IB Acquisition Corp. as of December 31, 2025.

Barclays PLC has filed an amended Schedule 13G, reporting beneficial ownership of 0.34% of IB Acquisition Corp's common stock.

TD Securities (USA) LLC and its affiliates have reported a complete divestment of their beneficial ownership in IB Acquisition Corp, now holding 0% of the common stock.

Bank of Montreal and its subsidiaries have reported a 6.17% beneficial ownership stake in IB Acquisition Corp. common stock.